Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0000914475-25-000021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-01-31 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | +2,294 | 43.1K | +6% | $0 |
| D | 2025-02-04 | 2025-01-31 | NBIX | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $152.94 | -1,207 | 41.9K | -3% | -$184.6K |
| D | 2025-02-04 | 2025-01-31 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | -2,294 | 2,294 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | M | A | 2,294 | $0.00 | 43,126 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-31 | S | D | 1,207 | $152.94 | 41,919 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) Includes an aggregate of 54 shares purchased on August 31, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 3 | Derivative | Restricted Stock Unit | 2025-01-31 | M | D | 2,294 | $0.00 | 2,294 | D | — · — to — | 2,294 Common Stock | (F4) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F5) This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award. |